Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Immune checkpoint inhibitor (ICI) therapies, including the programmed cell death protein 1 (PD-1) axis blockade, are considered a major oncological breakthrough of the early twenty-first century and have led to remarkable response rates and survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the available therapies wo...
Alternative Titles
Full title
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2480749204
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2480749204
Other Identifiers
ISSN
0945-6317
E-ISSN
1432-2307
DOI
10.1007/s00428-021-03030-8
